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1. Introduction 
According to World Health Organization (WHO 2007), tumors of the nervous system are 
classified into seven major groups including primary tumors (neuroepithelial, meningeal, 
cranial nerves, paraspinal nerves, germinal, region sellar and hematopoietic) and the 
secondary tumors or metastatic.  
The primary tumors of the nervous systems are relatively rare. According to data from the 
Central Tumor Registry of the Central Nervous System from Unites States (CBTRUS 2011), it 
is estimates that about 64.530 new cases (approximately 22.020 of them malignant) 
diagnosed in 2010, representing 1.44% of all malignancies diagnosed in this country. Despite 
the low incidence, malignant primary tumors are highly lethal - responsible for about 13.140 
deaths in the Unites States in 2010.   
Gliomas are tumors that arise from glial cells and include astrocytomas, 
oligodendrogliomas, oligoastrocitomas (also called mixed gliomas) and ependymomas. 
Gliomas are among the group of neuroepithelial tumors and account for 31% of primary 
tumors and 80% of malignant tumors of the nervous system. The astrocytoma group 
represents 76% of all gliomas, and glioblastoma represents 53.7% of cases (CBTRUS 2011). 
Glioblastoma is the most frequent and malignant astrocytoma, and despite numerous 
advances in the diagnosis and treatment of these tumors, their prognosis remains limited 
(Brandes et al. 2008; Wen; Kesari, 2008).  
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It is described that the glioma is the most common neoplasm of the human central nervous 
system (CBTRUS 2011), being difficult therapeutic approach, due to several factors: i) 
presenting infiltrative ii) possess tumor composed of cells with different morphofunctional 
characteristics that express a variety of neural markers, iii) be highly resistant to 
radiotherapy and chemotherapy procedures (Singh et al., 2003). 
Glioblastoma cell lineages express a set of cell surface antigens also found in mesenchymal 
stem cells (MSC), such as CD29, CD44, CD73 (SH3, SH4), CD90 (Thy-1) and CD105 (SH2) 
(Sordi et al., 2005). In addition, a small population of cancer stem cells has been identified in 
brain (Singh et al., 2004). Some evidence suggests that CD133 is a marker for a subset of 
glioblastoma cancer stem cells. The MSC-like phenotype and CD133 positive cells isolated 
from human glioblastoma may play a role in tumorigenesis or tumor recurrence and could 
be a potential target for therapies for glioblastoma.  The transcription factor Forkhead 
BoxM1 (FoxM1) also has been described as up-regulated in glioblastoma cells and may act 
as a malignancy marker. 
Nanobiotechnologic technologies can offer excellent tools for evaluating and understanding 
tumorigenesis, tumor mapping and tumor behaviour. One example is the use of 
superparamagnetic iron oxide nanoparticles (SPIONS). Recently, SPIONs have attracted 
attention for their use in nanotechnology (Tartaj et al., 2003) and biomedical applications, 
including drug delivery (Voltairas et al., 2002), hyperthermia in cancer treatment (Jordan et 
al., 1997; Jordan et al., 1999) and as image contrast agents in magnetic resonance imaging 
(MRI) (Cheng et al., 2005; Kumar et al., 2007).  
It was also used in this study, superparamagnetics iron oxide nanoparticles for cell 
separation process with MACS Technology. Applying the magnetic cell sorting (MACS) 
technology, we reported results of purifying the CD133 positive cells from the glioblastoma 
cells. In malignant brain tumors, CD133 has been suggested to be a cancer stem cell marker, 
since only CD133 positive cells from brain tumor biopsy material were able to initiate brain 
cancer in a mouse model (Singh et al., 2004). Prominin-1 (PROM-1), also called CD133, is a 
protein with several isoforms of unknown physiological or pathological function, and is 
localized both in the cytoplasm and at the cell surface (Miraglia, et al. 1997). It is expressed 
by human neural stem cells and has been proposed to have a function in central nervous 
system development. 
Another possible nanobiotechnologic tool of great relevance are the Quantum Dots (QD). 
Semiconductor QDs are nanoparticles that have attracted widespread interest in biology and 
medicine due to their unique optical and electronic properties. These properties, especially 
their reduced tendency to photobleach and the dependence of their fluorescence wavelength 
on their size, make them suitable for fluorescent probing applications to detect cancer 
biomarkers in vitro and in vivo in cells. Thus, the QD act as probes which are detectable by 
the optical techniques of spectroscopy and magnetic resonance imaging (Lee et al., 2007) 
including the technique of transmission electronic microscopy (TEM), due to the 
nanoparticles’ electrondensity (Nisman et al., 2004).  
The present study analyzed the use of nanoparticles for labelling human glioblastoma cell 
lineages (U87MG/A172). For this purpose, we used SPIONs, as well as monoclonal 
antibodies (CD29, CD44, CD105) or FOXM1 conjoined to secondary antibodies linked to 
quantum dots. This strategy was based on complete glioblastoma immunophenotypic 
profile determined by flow cytometry. Then, the analysis was performed by transmission 
electron microscopy and immunofluorescence glioblastoma cells using superparamagnetic 
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nanoparticles, SPIONs and QD. We also described the immunolocalization of CD133 
epitopes in cells from primary cultures derived from human glioblastoma. 
2. Material and methods 
2.1 Culture and labelling human glioblastoma lineages with quantum dots (QD) 
The cell lines of human glioblastoma (U87MG and A172) were maintained in a culture of 
DMEM-LG: Dulbeccos Modified Eagle Medium Low Glucose to 10% Fetal Bovine Serum 
and 1% Antibiotic-Antimycotic (100X) and 200nM L-Glutamine (100X).  
Human glioblastoma cells were labeled in the culture after their expansion and adhesion to 
the culture plate according to the manufacturer's instructions (Invitrogen). Briefly, cells were 
incubated with primary antibodies, such as CD29, CD44 and CD105 followed by incubation 
with secondary antibodies (pure goat anti-mouse, IgG) linked to quantum dots (QD 565nm).  
The lineages were labeled for the transcription factor FOXM1 (Zimed - Invitrogen), which 
was conjoined in advance with quantum dots (QD 525nm) according to the directions of the 
QD Antibody Conjugate Kit (Invitrogen).  
The labeled glioblastoma cells were maintained in a humidified incubator (Thermo Fisher 
Scientific Inc. 3110, Waltham, MA) with 5% CO2 at 37°C for 24 hours and subsequently fixed 
in 1% glutaraldehyde for later analysis in TEM (Philips CM100). 
2.2 SPIONs synthesis and glioblastoma lineages labelling 
The colloidal suspensions based on SPIONs (Fe3O4) were previously synthesized by the sol-
gel process. These syntheses included the rapid hydrolysis of Fe3+, by the addition of 
ammonium hydroxide to the 0.2 M FeCl3H2O aqueous solution in the presence of a 
surfactant (dextran). The dialysis of the precipitate permitted its peptizing leading to the 
formation of a colloidal suspension with SPIONs which have a diameter of 6 nm.  
Thus, the tumor cells lineages were labeled in the culture with a concentration of 0.5% 
SPIONs and kept in a humidified incubator (Thermo Fisher Scientific Inc. 3110, Waltham, 
MA) with 5% CO2 at 37°C for 24 hours. Subsequently, they were fixed in 4% 
paraformaldehyde and stained with 5% Prussian blue, viewed under a light microscope 
(OLYMPUS IX51), and fixed in 1% glutaraldehyde for later analysis under a TEM (Philips 
CM100). 
2.3 The immunophenotyping of glioblastoma lineage cells by flow cytometry 
The established glioblastoma lineage cells were analyzed for the cell-surface expression of 
typical mesenchymal stem cell protein markers. These experiments were conducted using 
monoclonal antibodies commercially available. The staining technique followed the 
manufacturer’s instructions. Briefly, the samples in the 4th stage were harvested by a 
treatment with 0.25% Tryple Express (GIBCO-Invitrogen, Carlsbad, CA), washed with PBS 
(pH= 7.4) and stained with the selected monoclonal antibodies and incubated in the dark for 
30 minutes at 4oC. Cells were then washed and fixed with 1% paraformaldehyde. The 
following human antibodies were used: CD14-FITC (clone: M5E2; BD Pharmingen – San 
Diego – CA), CD29-PE (clone: MAR4; BD Pharmingen – San Diego – CA), CD31-PE (clone: 
WM59; BD Pharmingen – San Diego – CA), CD34-PE (clone: 581; BD Pharmingen – San 
Diego – CA), CD44-PE (clone: 515; BD Pharmingen – San Diego – CA), CD45-PerCP-Cy5 
(clone: 2D1; Biosciences – San Jose – CA), CD73-PE (clone: AD2; BD Pharmingen – San 
Diego – CA), CD90-APC (clone: 5E10; BD Pharmingen – San Diego – CA), CD106-FITC 
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(clone: 51-10C9; BD Pharmingen – San Diego – CA), CD166-PE (clone: 3A6; BD Pharmingen 
– San Diego – CA), HLA-DR-PerCP-Cy5 (clone: L243; Biosciences – San Jose – CA) and 
CD105-PE (clone: 8E11; Chemicon – Temecula - CA).   
The data acquisition was carried out by FACSARIA flow cytometry equipment (BD 
Biosciences, San Jose, CA) and data analyses were performed using FACSDIVA software 
(BD Biosciences, San Jose, CA) or Flow Jo Software (TreeStar, Ashland, OR).  
2.4 Culture of primary glioblastoma cells 
Glioblastoma tumor cell samples were washed with 1%PBS and the enzymatic dissociation 
was performed in 0.3% collagenase. The obtained cells were them resuspended in 
Dulbecco's Modified Eagle's Medium (DMEM-Low Glucose) and plated at a density of 3x106 
live cells/60mm plate. 
2.5 Magnetic cell separation using MACS (Miltenyi Biotec) 
The culture of primary glioblastoma cells were purified following the separation protocol by 
MiniMACS microbeads affinity chromatography using anti-CD133 bound to magnetic beads 
(Miltenyi Biotec). 
The cells were filtrated in 30µm nylon filters and the cell number was determined by an 
automatic cell counter (Coulter).  Afterwards, the cells were centrifuged (400g for 5 minutes) 
and resuspended 300 µL of PBS solution containing 2 mM EDTA and 0.5% BSA (solution 1) for 
each 108 cells. The next step was the addition of 100 µL of FcR blocker and 100 µL of magnetic 
micro-spheres with CD133+ antibodies, followed by the incubation at 6°C for 30 minutes.  
After incubation, the labelled cells were centrifuged and resuspended in solution 1 to be 
separated in the chromatography column to isolate only the CD133+ cells. The selected 
CD133+ cells were subsequently fixed in 1% glutaraldehyde for later analysis in a TEM. 
2.6 Immunocytochemical staining of primary culture glioblastoma 
Glioblastoma tumor samples were washed 1% PBS and tumor cells were disaggregated in a 
solution containing 0.3% collagenase in 1% PBS buffer. Cells derived from the tumor were 
then resuspended in Dulbecco's Modified Eagle's Medium (DMEM -Low Glucose) and 
plated at a density of 3x106 live cells/60mm plate. Cells were fixed with 4% 
paraformaldehyde and stained with antibody against CD133/1 (human monoclonal IgG1; 
1:1000 dilution; Miltenyi Biotec). After washing, the cells were incubated with KIT 
Advanced TMHRP Dako (K4067) Advanced TMHRP Enzyme and followed by the application 
of the substrate-chromogen solution (DAB+). 
2.7 QD labelled primary culture glioblastoma by fluorescence microscopy: 
Primary antibodies CD29 in conjunction with the secondary (anti-mouse IgG) linked to 565nm 
nanocrystals QD (Qtracker 565 Cell Labelling Kit, Invitrogen, Carlsbad, CA) were used to label 
of the primary culture glioblastoma according to the manufactory’s instruction. The labelling 
of glioblastoma cells was detected by using a fluorescence microscopy (IX51 Olympus) with a 
filter for detection of the QDs (QD655-A-OMF-ZERO filter, Semrock, Rochester, NY).  
2.8 Transmission electron microscopy: 
Glioblastoma lineages (107 cells) were fixed in 1% glutaraldehyde and 0.2M cacodylate 
buffer for two hours at 4°C. Cells were washed in cacodylate buffer, 2 times for 15 minutes 
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each. Post-fixation was performed in 1% osmium tetroxide for one hour at 4°C, followed by 
another two 15 minute washes in the same buffer. For contrast, the pellet was immersed in a 
solution of uranyl acetate in acetone for 30 minutes. After dehydration, the material was 
embedded in Epon resin diluted in acetone (1:1) and incubated at 4°C with agitation for 24 
hours. The pellet was then transferred to pure Epon resin and incubated at 60° C for 72 
hours, until completely polymerized. Semi and ultrathin sections were obtained with the aid 
of a Porter Blum ultramicrotome. The semithin sections were stained with azur II (1%) and 
methylene blue (1%). The ultrathin sections were placed on copper grids and stained with 
uranyl acetate and lead citrate. The grids were studied and photographed under a TEM 
(PHILIPS CM100). 
3. Results 
3.1 The immunophenotypic profile of glioblastoma lineage cells: 
The glioblastoma lineage cells were analyzed by flow cytometry and gated according their 
granularity versus size, and then followed by the surface markers analysis. These cells were 
analyzed for the expression of cell membrane proteins and found to be positive for the 
expressions of CD29, CD44, CD73, CD90, CD105, which are generally considered as a 
marker set for mesenchymal stem cells (Figure 1).   
 
 
Fig. 1. Expression of mesenchymal markers as CD29, CD44, CD73, CD90 and CD105 on the 
cell of glioblastoma lineage A172 (A). Besides a variation on the percentage of CD73 and 
CD90, the same markers were found on the glioblastoma lineage U87MG (B). 
3.2 Glioblastoma labelling by using monoclonal antibodies such as CD29, CD44, 
CD105 and the transcription factor FOxM1 conjugated to quantum dots (QD 565 nm 
and 525 nm) 
The analysis of ultrastructural immunolocalization revealed the presence of electrondense 
clusters on the surface of tumor cells (Figure 2B), as well as scattered in the cytoplasm 
(Figures 2D; 4B, C) and in the interior of the vesicles (Figures 2E; 4B, D, F). This 
electrondensity demonstrates the presence of monoclonal antibodies linked to QD.  
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Fig. 2. Ultrastructural analysis of glioblastoma lineages marked with nanocrystal quantum 
dots (QDs) using TEM. B) QDs (565nm) conjoined with the CD29 monoclonal antibody. D, 
E) QDs (565nm) conjoined with the CD44 monoclonal antibody. G, H) QDs (525nm) 
conjoined with the FOxM1 transcription factor. A, C, F) Glioblastoma lineage cells of the 
control group. A, B, C, H) Scale: 0.25µm. D, E, G) Scale: 0.5µm. F) Scale: 2µm. n = nucleus; c 
= cytoplasm; nu = nucleolus; v = vacuole; ve = vesicle; arrow = electrondense nanoparticles 
(nanocrystals). 
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Figure 4B shows the presence of vesicles from the process of invagination of plasmic 
membrane.  
Electrondense clusters were not observed in our control group U87MG and A172 lineage 
cells, which did not receive the QDs (Figures 2A, C, F; 4A). These QDs can also be associated 
with cytoplasmic organelles such as the rough endoplasmic reticulum (Figure 4E). 
The transcription factor FOxM1 can also be evidenced by the QD electrondensity conjoined 
to this nuclear transcription factor. This compound can be observed by granules in various 
regions of the tumor cell nucleus (Figures 2G, H). 
The figures 3A,B e C shows, by fluorescence microscopy, the glioblastoma cell membrane 
staining by both CD29 primary antibody and the secondary anti-mouse antibody and, as a 
control, the glioblastoma cells were stained with the secondary anti-mouse antibody only 
(Figure 3D). The analysis of ultrastructural revealed the presence of electrondense clusters 
on the surface of tumor cells (Figure 3E) staining by of the primary antibody CD29 and 
secondary anti-mouse polyclonal antibody. Electrondense clusters were not observed in 
control group (Figure 3F), depicts the glioblastoma cells stained with the secondary  
anti-mouse antibody only, showing no unspecific staining by this antibody in these 
experiments.  
3.3 Primary culture glioblastoma marked with superparamagnetic nanoparticles using 
anti-CD133 bound to magnetic beads 
The analysis of immunocytochemistry demonstrated CD133 expression in primary culture 
glioblastoma (Figure 5B). Under the electron microscopy, ultrastructural analysis 
highlighted the presence of electrondense granules in the glioblastoma cell surface. This 
demonstrates the presence of anti-CD133 monoclonal antibodies bound to 
superparamagnetic nanoparticles recognizing the CD133 membrane protein (Figures 5D, E). 
This does not occur in the cells of the control group (CD133-) (Figure 5C). Electrondense 
signals related to superparamagnetic nanoparticles were also observed in the cell cytoplasm, 
suggesting their internalization through the process of the endocytosis of QD bound to the 
antibodies (Figures 5D, E). CD133+ cells incorporated superparamagnetic nanoparticles 
through its small cytoplasmic projections forming the pinocytics vesicles, as shown in the 
figures 5E and 5F.   
3.4 The glioblastoma lineage iron oxide superparamagnetic nanoparticles (SPIONs) 
markings 
The analysis of light microscopy, with Prussian blue staining, revealed large amounts of 
iron oxide nanoparticles dispersed in the cytoplasm of tumor cells (Figure 6B), compared to 
cells from the control group (Figure 6A). 
The ultrastructural SPIONs markings, using electrondensity resources, confirmed the 
presence of these nanoparticles, mainly in the interior of the vesicles (Figures 6D, E, F, G), 
that did not occur in the control group cells (Figure 6C). Figure 4D showed the process of 
internalization of the nanoparticles, as well as invaginations of the plasma membrane and 
subsequent vesicle formation. 
Some cells showed intense cytoplasmic vacuolation (Figure 6G), loss of cell boundaries or 
disintegration of the plasmic membrane (Figure 6F), and the formation of concentric 
lamellae forming myelin figures (Figure 6H). 
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Fig. 3. Immunofluorescence and ultrastructural analysis of glioblastoma lineages marked 
with nanocrystal quantum dots (QDs). A, B, C, E) 565nm QDs conjoined with the CD44 
monoclonal antibody. D, F) Glioblastoma cells with the secondary anti-mouse only. A, B, C, 
D) 600X. E, F) Scale: 0.25µm. 
www.intechopen.com
 
Immunolocalization of the Glioblastoma Cells by Nanoparticles Using Microscopy Tools 
 
333 
 
 
 
 
Fig. 4. B-F) Ultrastructural analysis of glioblastoma lineages marked with nanocrystal 
quantum dots (QD 565nm) conjoined with the CD105 monoclonal antibody. A) 
Glioblastoma lineage cells of the control group. A, C, D, E, F) Scale: 0.5µm. B) Scale: 1µm. n = 
nucleus; v = vacuole; mi = mitochondria; ve = vesicle; mf = microfilaments; fm = myelin 
figure; rer = rough endoplasmic reticule; arrow = electrondense nanoparticles 
(nanocrystals). 
www.intechopen.com
 
Diagnostic Techniques and Surgical Management of Brain Tumors 
 
334 
 
 
 
Fig. 5. Analysis of primary culture glioblastoma marked with microbeads CD133 by using 
immunocytochemical staining and transmission electron microscopy. (A, C) Primary culture 
glioblastoma of the control group. (B, D–F) Glioblastoma cells (CD133+). (A, B) 400. Scale 
bars: (C) 0.25 µm; (D, E) 0.5 µm; (F) 1 µm. n, nucleus; c, cytoplasm; mi, mitochondria. 
Arrows indicate electrondense nanoparticles. 
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Fig. 6. Glioblastoma lineages marked with SPIONs. A, B) Light microscopy using Prussian 
blue staining. A, C) Glioblastoma lineage cells of the control group. A, B) 600X. C-H) 
Transmission electron microscopy. C-G) Scale: 1µm; H) Scale: 0.25µm. n = nucleus; v = 
vacuole; ve = vesicle; fm= myelin figure; mi = mitochondria; * = cell margin; arrow = 
electrondense nanoparticles. 
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4. Discussion 
Glioblastoma is the most malignant brain tumor (Louis et al., 2007). Because of its invasive 
nature, it cannot be completely removed, reducing the success of chemo and/or 
radiotherapy procedures (Louis et al., 2007).  
Some nanobiotechnology resources, using nanoparticles in the process of cell labelling, can 
be extended to areas of neuro-oncology trough the study of tumorigenic cells in the 
immunolocalization process (Simberg et al., 2007).  
Our study suggests new approaches for the identification of the glioblastoma cells by 
ultrastructural examination using nanobiomarkers and it can contribute for further in vivo 
studies by understanding glioblastoma staining process. 
Immunophenotypically, the glioblastoma lineages express a set of cell surface antigens also 
found in mesenchymal stem cells (MSC), such as CD29 (β1 integrin - receptor protein of 
extracellular matrix and a cell to cell interaction mediator), CD44 (hyaluronate receptor), 
CD73 (SH3, SH4), CD90 (Thy-1) and CD105 (SH2) (Sordi et al., 2005). These finding suggest 
that a subset of primary glioblastoma derives from transformed cells containing MSC-like 
properties with partial phenotypic aspects of the MSC.  
Alternatively, glioblastomas cells could activate a series of pathways that result in the 
establishment of the cancer cells mesenchymal phenotype which may contributes to the 
tumor growth and malignant progression (Tso et al., 2006). Thus, MSC-like phenotype may 
play a role in tumorigenesis, invasive progression or tumor recurrence. 
The analysis of ultrastructural immunolocalization of glioblastoma lineages showed the 
presence of monoclonal antibodies CD29, CD44 and CD105 linked to quantum dots, i.e., 
electrondense clusters on the surface of tumor cells and in vesicles. 
The electronic micrographs described an important ultrastructural finding related to the 
presence of vesicles that internalize QD by the process of pinocytosis for all antibodies 
tested. We suggest that in our study the pynocytisis occur by receptor-mediated 
endocytosis. The endocytosis process happens after the antibody biding to the receptor, and 
then a depression arises on the cell membrane which is followed by the formation of the 
pinocytic vesicles. These pinocytic vesicles that are surrounded by the cytoplasmic proteins 
called clatrines are internalized. 
Immunolocalization of the process by marking cells with CD29 primary antibody described 
control parameters for the study. This figure 6 shows, by microscopy fluorescence, the 
membrane staining by both CD29 primary antibody and the secondary anti-mouse antibody 
and, as a control, the cells were stained with the secondary anti-mouse antibody only. These 
results show that there is no unspecific reaction by the anti-mouse secondary polyclonal 
antibody in this experiment. The electronic micrographs also described the cells stained with 
the primary antibody CD29 and secondary anti-mouse polyclonal antibody, which the cells 
stained with the secondary anti-mouse antibody only, showing no unspecific staining by 
this antibody in these experiments. 
The CD44 monoclonal antibody selected for this study is a transmembrane glycoprotein 
which acts primarily as a recipient of hyaluronana, and can bind to certain other ligands in 
an extracellular matrix. A correlation between the particular pattern of CD44 variants 
produced by strains of glioblastoma cells and tumor clinicopathological parameters, such as 
cell motility, invasive properties, potential for metastasis, and tumor cells survival could be 
established (Rudzki et al., 1997). 
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The CD105 monoclonal antibody, also included in this study, is intensely expressed in the 
tumor vascular system and can be an important indicator of prognosis of glioblastoma 
malignancy (Margaritescu et al., 2008). 
Tumor growth and metastasis depend on the formation of new blood vessels. Tumor cells 
release a variety of compounds, which can act on endothelial progenitor cells activation, 
proliferation, and migration promoting neovascularization and consequent tumor 
angiogenesis (Reddy et al., 2006). Our study suggests the use of QD for tumor accumulation 
mechanism studies as well as targets for vascular mapping and consequent removal of 
tumorigenic glioblastoma cells. 
Our study also proposes the use of a transcription factor called Forkhead Box M1 (FoxM1) 
previously conjoined with QD, as a glioblastoma marker, since this factor is described as up-
regulated in glioblastoma cells (Liu et al., 2006). FoxM1 was ultrastructurally evident by the 
nanocrystal electrondensity conjoined to this nuclear transcription factor.  
Reports showed that the level of protein expression in human gliomas tissues was directly 
related to the tumor grade or the glioblastoma cells tumorigenicity and may act as an index 
of tumor malignancy. 
The electronic micrographs also demonstrated that glioblastoma cell lineages internalize the 
QD, expressing them ultrastructurally as electrondense structures that are located in 
different cellular regions, such as the cytoplasm or the rough endoplasmic reticulum.  
The same process of tumor QD-marking was described by Jackson, et al. (2007) where the 
nanocrystals were phagocytised by macrophages and microglia, thus infiltrating 
experimental gliomas. Therefore, his study suggests the use of non-conjoined nanocrystals 
to assist the imaging system for surgical termination or glioblastoma tumor biopsies. 
The analysis of immunocytochemistry demonstrated the CD133 expression in primary 
culture glioblastoma. Ultrastructural results showed anti-CD133 bound to the SPIONs by 
the presence of electrondense granules in cell membrane, as well as in the cytoplasm or 
forming vesicles.  
CD133 localization in membrane protrusions suggests an involvement in the dynamic 
organization of membrane and therefore in the mechanisms influencing cell polarity, 
migration and interaction of stem cells with neighboring cells and/or extracellular matrix, 
but experimental data are currently lacking. In addition, it is not known whether CD133 has 
a role in self-renewal and differentiation of stem cells, witch has important implication in 
gliomagenesis (Singh et al., 2003; Beier et al., 2007; Zeppernick et al., 2008). 
CD133  positive cells isolated from human brain tumours exhibit stem cells properties in 
vitro (Singh et al., 2003) and are able to initiate and drive tumor progression in vivo (Singh et 
al., 2004) strongly suggesting that CD133 positive cells might be the brain tumor initiating 
cells. This notion has been recently challenged by studies demonstrating that glioblastoma 
CD133 negative cells have also properties of stem cells and are tumorigenic when engrafted 
intracerebrally into nude mice (Beier et al., 2007). 
Zeppernick, et al. (2008), for the first time, presented a direct link between the expression of 
a cancer stem cell antigen CD133 and patient survival in gliomas, giving support to the 
current cancer stem cell hypothesis. The authors demonstrated that the proportion of CD133 
positive cells was an independent risk factor for tumor regrowth and time course of 
malignant progression in WHO grade 2 and 3 tumors. These data provide strong supportive 
evidence for image mapping the cancer stem cell structural model and the clinical relevance 
of the CD133 positive cell population in glioblastoma. 
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Iron oxide superparamagnetic nanoparticles (SPIONs) were also targets in the marking of 
glioblastoma cells. The SPIONs were enclosed by tumor cells through endocytosis and 
revealed by the Prussian blue cytochemical staining or the ultrastructural electrondensity 
resource within the vesicles. 
Our work suggests the use of SPIONs as a contrast agent in magnetic resonance imaging 
techniques through the internalization of iron oxide by the endocytosis process (fluid phase 
- mediated receptor for transferrin linked to the oxide iron) (Daldrup-Link et al., 2003).   
Transmission electron microscopy studies, using iron oxide-based markers, revealed no 
significant morphostructural changes in the tumor marked cells (Zeppernick et al., 2008). 
The results for the glioblastoma lineage markings by SPIONs describe, however, intense 
cytoplasmic vacuolation, loss of cell boundaries or disintegration of the plasma membrane 
and the formation of concentric lamellae forming myelin figures. Such indicators suggest 
ultrastructural signs of cell death probably derived from the process of marking, 
corroborating findings in the Alzheimer's disease studies using magnetic nanospheres 
(Hartig et al., 2003). 
The ultrastructural findings of the tumorigenic glioblastoma cell labelling process using 
quantum dot and SPIONs suggest that these nanobiomarkers can play important role in 
cancer diagnosis and also help to understand tumor behavior, i.e., biomimetic amplification 
of tumoral "homing" revealing tumor invasive properties and its potential for metastasis, 
recognizing vascular targets for image mapping and treatment of brain tumors (Simberg et 
al., 2007),  and describing the tumorigenicity of glioblastoma through therapeutic indicators 
of tumor malignancy (Voura et al., 2004; Simberg et al., 2007),   
The process of tumor cell labelling in vitro by nanoparticles, using microscopic analysis, can 
successfully contribute in the future to the identification of the tumorigenic cells and 
consequently for better understanding glioblastoma genesis and recurrence. In addition, this 
method may help further studies in tumor imaging, prognostic markers detection, as well as 
to understand the selection process and isolation of the brain tumor stem cell (CD133+) 
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